Zydus Lifesciences Ltd acquires UK-Based LiqMed for GBP 68 Million

Ahmedabad: The Gujarat-based pharmaceutical company, Zydus Lifesciences Limited, has announced its acquisition of the LiqMeds Group of companies based in the UK for a consideration of GBP (sterling pounds) 68 million.

This acquisition was completed through Zydus’ wholly-owned subsidiary, Zydus Pharmaceuticals UK Limited, as disclosed in their stock exchange filing. LiqMeds specializes in the development, manufacturing, and distribution of oral liquid products for the global market, which it currently sells through its partners.

A subsidiary of the group, LM Manufacturing Limited (LMML), operates a manufacturing facility for oral liquid products in Weedon, Northampton, UK, supplying products to both the US and UK markets. Zydus will make an initial payment of GBP 68 million, along with annual earn-outs until 2026, contingent on the achievement of specific predetermined milestones related to the acquisition of the LiqMeds Group of companies. This transaction will result in an increase in earnings per share (EPS) for Zydus starting from the first year of the acquisition. DeshGujarat